Therapeutic immunosuppression of T cells.
Current immunosuppressive therapy carries a range of unwanted side effects, and tends to penalize the whole immune system. It is desirable to develop therapies that are more selective for antigen-reactive cells. As T lymphocytes use a wide range of surface receptors to interact with antigen-bearing cells and with each other, much interest is devoted to trying to develop agents that selectively block the interaction of these receptors with their ligands, and others that could be used to reprogram the immune system so that it might become tolerant to the antigens rather than attack them.
Department of Pathology, University of Cambridge, UK.
H
H
Waldmann
S P
SP
Cobbold
D
D
Wraith
J
J
Isaacs
D000818:Animals; D000911:Antibodies, Monoclonal; D006801:Humans; D007165:Immunosuppression Therapy / Q000379:methods*; D007167:Immunotherapy; D008954:Models, Biological; D016028:Receptors, Leukocyte-Adhesion / Q000187:drug effects / Q000502:physiology; D013601:T-Lymphocytes / Q000276:immunology*
D000911:Antibodies, Monoclonal; D016028:Receptors, Leukocyte-Adhesion